Triple-Negative Breast Cancer

>

Latest News

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.
Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC

March 22nd 2024

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.
Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

February 13th 2024

Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC

December 21st 2023

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.
Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC

December 7th 2023

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.
Pembrolizumab/Chemo Improves EFS Vs Chemo in High-Risk TNBC

October 20th 2023

More News